Navigation Links
Stem cells: Deathly awakening by interferon
Date:2/12/2009

After injuries with blood loss, the body quickly needs to restore the vital blood volume. This is accomplished by a special group of stem cells in the bone marrow. These hematopoietic stem cells remain dormant throughout their lives and are only awakened to activity in case of injury and loss of blood. Then they immediately start dividing to make up for the loss of blood cells. This has recently been shown by a group of scientists headed by Professor Andreas Trumpp of DKFZ.

Dormancy is an important protection mechanism of stem cells. First, it protects their genetic material from genetic alterations, which happen primarily during cell division. In addition, dormancy helps them escape attacks of many cytotoxins, which act only on dividing cells.

Scientists were still puzzling over which signaling molecules actually wake up stem cells from their dormancy. Andreas Trumpp and Marieke Essers from his team have now reported in Nature that interferon-alpha, a messenger substance of the immune system, acts like an alarm clock for hematopoietic stem cells. The scientists have thus shown for the first time that interferon-alpha can have a direct influence on the function of stem cells.

Interferon-alpha is released by immune cells when the organism is threatened by bacteria or viruses. The scientists triggered interferon production in mice by administering a substance that simulates a viral infection to the animals. Subsequently, there was a great increase in the division rate of hematopoietic stem cells. In control animals that were unable to process the interferon signals, the substance did not lead to an awakening of the stem cells.

The investigators obtained further proof of the effect of interferon-alpha using a drug called 5-fluorouracil, a cytotoxic substance frequently used for treating breast or bowel cancer. Dormant stem cells are resistant to the drug, which unfolds its effect only during division. However, if animals are given interferon-alpha prior to treatment with 5-fluorouracil, they die of anemia after a short time. This is because prior treatment with interferon forces quiescent stem cells into cell division, which sensitizes them for the effect of 5-FU and kills them. Thus, there are soon no more stem cells to keep up the supply of short-lived mature blood cells such as erythrocytes and blood platelets.

What researchers find particularly exciting about this finding is the prospect that the newly found working mechanism might help improve cancer treatment: "Using interferon-alpha, we might be able to wake up from dormancy not only hematopoietic stem cells but also tumor stem cells and, thus, break their frequently observed resistance to many anticancer drugs," Andreas Trumpp speculates.

A clinical observation already suggests that this assumption is more than just wishful thinking: Patients suffering from a type of blood cancer called chronic myelogenous leukemia who are treated with a drug called Gleevec almost always relapse after drug treatment has ended. Several patients were given interferon-alpha prior to the Gleevec treatment. Surprisingly, these patients experienced long relapse-free phases without any medication. "We believe that the leukemia stem cells were awakened by the interferon administration and, thus, were sensitized to elimination by Gleevec," Andreas Trumpp explains.


'/>"/>

Contact: Dr. Sibylle Kohlstdt
s.kohlstaedt@dkfz.de
Helmholtz Association of German Research Centres
Source:Eurekalert

Related medicine news :

1. Cancer stem cells: know thine enemy
2. Tai Chi & Qigong will play an important role in global awakening. - A New Earth, Eckhart Tolle, (Oprahs Book Club)
3. HALT-C researchers: Interferon as long-term treatment for hepatitis C not effective
4. Interferon needed for cells to remember how to defeat a virus, UT Southwestern researchers report
5. Only Half of MS Patients Respond to Interferon Therapy
6. Interferon Reduces, Eliminates Viral Infections in Heart Failure Patients
7. Study shows that high-dose, high-frequency interferon produces no additional benefit
8. GenOdyssee Receives Notice of Allowance from U.S. Patent Office for Improved Interferon-Alpha Aimed at Hepatitis C
9. PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy
10. Interferon does not slow or stop hepatitis C from worsening, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, ... relations, content marketing, social media management, corporate communications, SEO and cause marketing, is ... and in nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding ...
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, a global data ... that Premier Research, a leading clinical development service provider, has selected ERT’s Trial ... complex, due in part to an array of circumstances including the use of ...
(Date:2/23/2017)... , ... February 23, 2017 , ... CALNOC, the nation’s ... FACPE, will keynote their upcoming conference – Empowerment, Value and Collaboration – in Seattle, ... and CEO of the Virginia Mason Health System in Seattle since 2000. In addition ...
(Date:2/23/2017)... ... , ... Carlos Gutierrez has lived his spiritual life hardly without ... is the purpose of everyone in this universe. As Gutierrez sees the need of ... attempts to guide readers to expand one’s spiritual life. , “Our Spiritual Truths” deals ...
(Date:2/22/2017)... , ... February 22, 2017 , ... The Waismann ... the thousands of individuals who have recently fallen victim to America’s opioid epidemic. Now, ... Orange County, California, where they are free from the shame, stigma, and harmful ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... CITY, Calif. , Feb. 23, 2017 /PRNewswire/ ... pharmaceutical company focused on the development and commercialization ... acute pain, announced that it will release fourth ... on Thursday, March 2nd, 2017. AcelRx management will ... Eastern Time (1:30 p.m. Pacific Time) on March ...
(Date:2/23/2017)... COTTAGE, New York , February 23, 2017 /PRNewswire/ ... health implications arising from increasing caseload for varicose veins ... recorded across the globe are prompting the adoption of ... latest study on global endovenous laser therapy ... attention towards aftereffects of lifestyle choices and consequences of ...
(Date:2/23/2017)... Research and Markets has announced the addition of the "Global ... report to their offering. ... The Global Endoscopy Market is poised to grow at ... approximately $47.6 billion by 2025. This industry report ... on global as well as regional levels presented in the research ...
Breaking Medicine Technology: